Role of Tyrosine Kinase Inhibitors in Cancer Therapy

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1124/JPET.105.084145PMID 16002463
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.

  2005cited by this paper
• epidermal growth factor receptor

  2005cited by this paper
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cited by this paper
• In Vitro and In Vivo: The Story of Nonoxynol 9

  2005cited by this paper
• Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics.

  2005cited by this paper
• Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST

  2005influential reference
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma.

  2005cited by this paper
• Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

  2005cited by this paper
• The vascular endothelial growth factor family and its receptors.

  2004cited by this paper
• A phase 2, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy.

  2004cited by this paper
• Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule

  2004cited by this paper
• Molecular targeting of angiogenesis.

  2004cited by this paper
• BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

  2004cited by this paper
• Targeted cancer therapy

  2004cited by this paper
• The Role of Erlotinib (Tarceva, OSI 774) in the Treatment of Non-Small Cell Lung Cancer

  2004influential reference
• Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

  2004cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors

  2004influential reference
• Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC).

  2004cited by this paper
• AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.

  2004cited by this paper
• Dimerization of Cell Surface Receptors in Signal Transduction Review

  2004cited by this paper
• Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.

  2004cited by this paper
• BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience.

  2004cited by this paper
• Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

  2004cited by this paper
• Imatinib as a paradigm of targeted therapies.

  2004influential reference
• Wilms' tumor in adults: results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) Study.

  2004cited by this paper
• SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial.

  2004cited by this paper
• Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT).

  2004cited by this paper
• Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.

  2004influential reference
• TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC).

  2004cited by this paper
• New drugs for rheumatoid arthritis.

  2004cited by this paper
• Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016

  2004cited by this paper
• Vascular endothelial growth factor as a therapeutic target in cancer.

  2004influential reference
• Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor

  2004cited by this paper
• Targeting ErbB receptor interactions: A phase I trial of trastuzumab and erlotinib in metastatic HER2+ Breast Cancer.

  2004cited by this paper
• New drugs for rheumatoid arthritis.

  2004cited by this paper
• Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.

  2004cited by this paper
• Angiogenesis inhibitors in clinical development; where are we now and where are we going?

  2004influential reference
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Erlotinib (Tarceva): an update on the clinical trial program.

  2003cited by this paper
• The impact of anti-angiogenic agents on cancer therapy

  2003cited by this paper
• Overview of targeted therapies for cancer.

  2003cited by this paper
• A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

  2003cited by this paper
• In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

  2003cited by this paper
• Targeting epidermal growth factor receptor--are we missing the mark?

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Rituximab in chronic lymphocytic leukemia.

  2003cited by this paper
• Treating seizures in patients with brain tumors: Drug interactions between antiepileptic and chemotherapeutic agents.

  2003cited by this paper
• Role of FLT3 in leukemia.

  2002cited by this paper
• Mutations of the BRAF gene in human cancer

  2002cited by this paper
• Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.

  2002cited by this paper
• Smart drugs: tyrosine kinase inhibitors in cancer therapy.

  2002cited by this paper
• Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.

  2002cited by this paper
• Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.

  2002cited by this paper
• Sti‐571 in Chronic Myelogenous Leukaemia

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002influential reference
• Advances in the biology and treatment of myeloma bone disease.

  2002cited by this paper
• Regulation and targets of receptor tyrosine kinases.

  2002cited by this paper
• ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.

  2002cited by this paper
• Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

  2002influential reference
• RANK‐Fc in myeloma

  2002cited by this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cited by this paper
• The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

  2001cited by this paper
• Tyrosine kinase inhibitors—ZD1839 (Iressa)

  2001influential reference
• Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.

  2001cited by this paper
• The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.

  2001cited by this paper
• Angiogenesis and leukemia.

  2001cited by this paper
• Epidermal growth factor receptor signaling.

  2001cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• CI-1033, a pan-erbB tyrosine kinase inhibitor.

  2001cited by this paper
• Oncogenic kinase signalling

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer.

  2001cited by this paper
• Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

  2000influential reference
• The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.

  2000cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• The biology of chronic myeloid leukemia.

  1999influential reference
• SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.

  1999cited by this paper
• Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha.

  1998cited by this paper
• Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

  1998cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy.

  1997cited by this paper
• Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.

  1997cited by this paper
• Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

  1997cited by this paper
• Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

  1996influential reference
• Signaling by Receptor Tyrosine Kinases

  1993cited by this paper
• A Look Ahead

  1979cited by this paper
• Epidermal growth factor

  1972cited by this paper
• OF PHASE 2 CLINICAL STUDY

  year unknowncited by this paper

• Perioperative Management of Targeted and Immunologic Agents in Neurosurgical Oncology.

  2026cites this paper
• İlaçlara Bağlı Çene Kemiği Osteonekrozu: Etken İlaç Grupları, Tanı ve Tedaviye Dair Görüşler ve Kavramlar

  2026cites this paper
• Higher Purity of Phosphatidylserine Improves Human Cortical Neuron Function by Modulating SIRT1-PGC-1α Pathways.

  2026cites this paper
• Recent Advances in Pyridine and Pyrimidine Based Scaffolds as c-Met Kinase Inhibitors for Cancer Therapy: Biological Insights, Docking and SAR

  2026cites this paper
• HER3 and FOLR1 Expression as Actionable Targets in High-Grade Serous Ovarian Carcinoma: Prognostic and Therapeutic Implications

  2026cites this paper
• Risks of Retinal Vascular Occlusions with the Systemic Use of Tyrosine Kinase Inhibitors.

  2026cites this paper
• “Next-Generation Cord Blood Expansion: Bridging the Cell Dose Gap with Bioengineered Niches and Clinical Breakthroughs”

  2026cites this paper
• Physicochemical characterization, cyclodextrin complexation, and protonation state-dependent receptor binding of selected tyrosine kinase inhibitors

  2026cites this paper
• Potential impact of tyrosine kinase inhibitors on glycemic control and diabetes mellitus progression: a clinical appraisal

  2025cites this paper
• Hospital-Based Observational Study of Mucocutaneous Adverse Reactions of Tyrosine Kinase Inhibitors

  2025cites this paper
• Clinical Utility of Patient-Derived Cell-Based In Vitro Drug Sensitivity Testing for Optimizing Adjuvant Therapy in Dogs with Solid Tumors: A Retrospective Study (2019–2023)

  2025cites this paper
• Molecular interaction and esterase activity of bovine serum albumin with Pazopanib using multi-spectroscopic techniques and molecular docking

  2025cites this paper
• A literature review and update on medications related to osteonecrosis of the jaw independent of bisphosphonates and denosumab

  2025cites this paper
• Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

  2025cites this paper
• Explainable stacked-ensemble prediction of ABL1 tyrosine-kinase inhibitor resistance: A metaheuristic-optimized pipeline

  2025cites this paper
• Investigating the potential of the SI306 Src inhibitor and its liposomal formulation in the non-small cell lung cancer treatment.

  2025cites this paper
• Medicinal Chemistry Perspective of 1,8‐Naphthyridines as Anticancer Agents

  2025cites this paper
• Innovative nanoparticle-based therapies for pancreatic neuroendocrine tumours (PNETs): advances, challenges, and future directions

  2025cites this paper
• Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding.

  2025cites this paper
• PhosF3C: a feature fusion architecture with fine-tuned protein language model and conformer for prediction of general phosphorylation site

  2025cites this paper
• Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors

  2025cites this paper
• Contemporary trends on the kinase inhibitors with special reference to quinoxaline derivatives.

  2025cites this paper
• Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025)

  2025cites this paper
• Enhanced anti-cancer efficacy of Sorafenib and Pioglitazone via VEGF inhibition in DMBA-induced breast cancer model

  2025cites this paper
• Evaluation of oxadiazole-N-phenylacetamide conjugates as VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative assessment, molecular docking, and dynamics studies.

  2025cites this paper
• New 2-benzylideneamino-4,5-diphenylfuran-3‑carbonitrile derivatives and their benzylamino analogues: Synthesis, in vitro cytotoxicity, protein kinase inhibitory activity and in silico insights.

  2025cites this paper
• Endokrine Nebenwirkungen moderner Tumortherapien

  2025cites this paper
• The effect of healthcare professional-implemented interventions on adherence to oral targeted therapy in patients with cancer: a systematic review and meta-analysis

  2025cites this paper
• Regulation of hepatic organic anion transporting polypeptide 1B-type transport function by the protein kinase LYN.

  2025cites this paper
• Exploring the Anti-Cancer Mechanisms of Oxalis corniculata Through Integrated Network Pharmacology, Protein-Protein Interaction Network, and MCODE Cluster Analysis

  2025cites this paper
• Identification of silibinin and isotretinoin as potent up-regulators of sFRP4 (Wnt antagonist): In silico prediction and in vitro validation in breast cancer

  2025cites this paper
• Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study

  2025cites this paper
• Identification of the specific characteristics of neuroendocrine prostate cancer: Immune status, hub genes and treatment

  2025cites this paper
• The Application and Molecular Mechanisms of Mitochondria-Targeted Antioxidants in Chemotherapy-Induced Cardiac Injury

  2025cites this paper
• OncoFlow: A Multiplexed Microfluidic Platform for Personalized Drug Sensitivity Assessment.

  2025cites this paper
• Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia

  2025cites this paper
• Progress in Nanocarriers‐Based Approaches for the Delivery of Tyrosine Kinase Inhibitors in Bone Cancer: Trends and Prospects

  2025influential citation
• Muscle food-derived bioactive peptides for human health and well-being: a narrative review

  2025cites this paper
• Risk prediction of QTc prolongation occurrence in cancer patients treated with commonly used oral tyrosine kinase inhibitors: machine learning modeling or conventional statistical analysis better?

  2025cites this paper
• Tackling the Cardio-Kidney-Metabolic Burden in Cancer

  2025cites this paper
• Venotoclax associated hypothyroidism in a patient with acute myeloid leukemia

  2025cites this paper
• Molecular Mechanisms Regulating Epithelial Mesenchymal Transition (EMT) to Promote Cancer Progression

  2025cites this paper
• Indazol-Pyrimidine Hybrids: Design, Synthesis, and Antiproliferative Activity Against Human Cancer Cell Lines

  2025cites this paper
• Harnessing nanotechnology for efficient delivery of indole-based drugs in cancer treatment.

  2025cites this paper
• Mirk/Dyrk1B Kinase Inhibitors in Targeted Cancer Therapy

  2024cites this paper
• Machine Learning-Driven Predictions for Janus Kinase 3 Protein Drug Effectiveness

  2024cites this paper
• EGFR as therapeutic target to develop new generation tyrosine kinase inhibitors against breast cancer: A critical review

  2024cites this paper
• Anticancer evaluations of iodoquinazoline substituted with allyl and/or benzyl as dual inhibitors of EGFRWT and EGFRT790M: design, synthesis, ADMET and molecular docking

  2024cites this paper
• Single nucleotide polymorphisms conferring susceptibility to leukemia and oral mucositis: a multi-center pilot study of patients prior to conditioning therapy for hematopoietic cell transplant

  2024cites this paper
• A Comprehensive Review of Cancer Drug–Induced Cardiotoxicity in Blood Cancer Patients: Current Perspectives and Therapeutic Strategies

  2024cites this paper
• HER2 puzzle pieces: Non-Coding RNAs as keys to mechanisms, chemoresistance, and clinical outcomes in Ovarian cancer.

  2024cites this paper
• Discovery of Novel Pyrimidine Based Small Molecule Inhibitors as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-Cancer Studies.

  2024cites this paper
• Activity Alterations of 37 Tyrosine Kinase Inhibitors Upon kINPen Plasma Exposure in A549 Lung Cancer Cells

  2024cites this paper
• Mannose: A Promising Player in Clinical and Biomedical Applications.

  2024cites this paper
• A Case-Report Highlighting effects of PMF and Camel Milk on a Multiple Sclerosis Patient

  2024cites this paper
• Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review

  2024cites this paper
• PIKfyve controls dendritic cell function and tumor immunity

  2024cites this paper
• Cancer treatment-induced bone loss

  2024cites this paper
• ДОКІНГ ТА КВАНТОВО-ХІМІЧНІ ДОСЛІДЖЕННЯ ПРОТИПУХЛИННИХ МЕХАНІЗМІВ ПОХІДНИХ МОНОХЛОРООЦТОВОЇ ТА ДИХЛОРООЦТОВОЇ КИСЛОТ

  2024cites this paper
• Inducing apoptosis in acute myeloid leukemia; mechanisms and limitations

  2024cites this paper
• New vatalanib analogs: design, synthesis, in silico study and biological evaluation for anticancer activity

  2024cites this paper
• Synthesis, biological assessment, and in silico binding mode interaction analyses and DFT studies of biphenylsulfonamide-based potent MMP-2 inhibitors effective against chronic myeloid leukemia

  2024cites this paper
• Novel 1,2,3-triazole derivatives containing benzoxazinone scaffold: Synthesis, docking study, DFT analysis and biological evaluation

  2024cites this paper
• Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials.

  2024cites this paper
• Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

  2024cites this paper
• Protein tyrosine phosphatase PTPH1 potentiates receptor tyrosine kinase HER2 oncogenesis via a PDZ-coupled and phosphorylation-driven scaffold.

  2024cites this paper
• Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex

  2024cites this paper
• Endokrine Nebenwirkungen von Tumortherapien

  2024cites this paper
• PIKfyve, expressed by CD11c-positive cells, controls tumor immunity

  2024cites this paper
• Drug repurposing study of levofloxacin: Structural properties, lipophilicity along with experimental and computational DNA binding

  2024cites this paper
• Post-Market in vitro bioequivalence study of innovator and generic Gefitinib tablets: evaluation of JKN medicine quality

  2024cites this paper
• Recent advances in the use of tyrosine kinase inhibitors against thyroid cancer

  2024cites this paper
• Etoposide, cisplatin, and sintilimab combined with anlotinib in successful treatment of adrenocortical carcinoma with lung metastasis: a case report

  2024cites this paper
• Expanding the potential of pyridine scaffold for targeted therapy of cancer: Biological activity, Molecular insights, and Structure-activity relationship

  2024cites this paper
• Novel quinazolin-4-one based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity

  2024cites this paper
• Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors

  2024cites this paper
• Therapeutic Drug Monitoring of Sorafenib and Lenvatinib in Hepatocellular Carcinoma Patients – A Key to Personalised Pharmacotherapy

  2024cites this paper
• Prognostic Value of Baseline Skeletal Muscle Index in Colorectal Cancer Patients Treated with Fruquintinib: A multi-center real world analysis

  2024cites this paper
• New sulfonamide-based glycosides incorporated 1,2,3-triazole as cytotoxic agents through VEGFR-2 and carbonic anhydrase inhibitory activity

  2024cites this paper
• Underlying Mechanisms of Thrombosis Associated with Cancer and Anticancer Therapies

  2024cites this paper
• Development and Validation of HPTLC for the Determination of Gefitinib HCl in Tablet Dosage Form

  2024cites this paper
• Exploration of cytotoxicity of iodoquinazoline derivatives as inhibitors of both VEGFR‐2 and EGFRT790M: Molecular docking, ADMET, design, and syntheses

  2024cites this paper
• Historical Perspective and Current Trends in Anticancer Drug Development

  2024cites this paper
• In-vitro Antioxidant and Anticancer Studies of Date Palm (Phoenix dactylifera L.) Seed Extract and Its Oil on Seven Cell Lines with Molecular Docking Study Targeting PI3K and EGFR Inhibition

  2024cites this paper
• Molecular structure, spectroscopic, electronic and physicochemical properties of 7,8-dihydroxyflavone hydrate compound using first theory principle

  2023cites this paper
• Indole Antitumor Agents in Nanotechnology Formulations: An Overview

  2023cites this paper
• Discovery of new quinazoline derivatives as VEGFR-2 inhibitors: Design, Synthesis, and anti-proliferative studies.

  2023cites this paper
• Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.

  2023cites this paper
• Combination of venetoclax with BCR-ABL tyrosine kinase inhibitor as a therapeutic strategy for Philadelphia chromosome-positive leukemias

  2023cites this paper
• Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

  2023cites this paper
• Iodoquinazoline-derived VEGFR-2 and EGFRT790M dual inhibitors: Design, synthesis, molecular docking and anticancer evaluations.

  2023cites this paper
• New 1,3,4-thiadiazoles as potential anticancer agents: pro-apoptotic, cell cycle arrest, molecular modelling, and ADMET profile

  2023cites this paper
• Antiproliferative, molecular docking, and bioavailability studies of diarylheptanoids isolated from stem bark of Garuga pinnata Rox B.

  2023cites this paper
• Design, synthesis, docking, ADMET and anticancer evaluations of N-alkyl substituted iodoquinazoline derivatives as dual VEGFR-2 and EGFR inhibitors

  2023cites this paper
• Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics

  2023cites this paper
• Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction

  2023cites this paper
• Blood microsampling technologies: Innovations and applications in 2022

  2023cites this paper
• Exploring marine-derived compounds for MET signalling pathway inhibition in cancer: integrating virtual screening, ADME profiling and molecular dynamics investigations

  2023cites this paper
• Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series

  2023cites this paper
• Docking, Synthesis, and Evaluation of 4-hydroxy-1-phenyl-2(1H)-quinolone Derivatives as Anticancer Agents.

  2023cites this paper